A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

Trial Profile

A Multi-center, Uncontrolled Extension Study Evaluating Efficacy and Safety of SAR153191 in Patients With Active Rheumatoid Arthritis (RA)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Sarilumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms ABILITY; EXTEND; RA-EXTEND; SARIL-RA-EXTEND
  • Sponsors Regeneron Pharmaceuticals; Sanofi
  • Most Recent Events

    • 16 Jun 2018 Results of pooled analysis from four studies (MOBILITY, TARGET, EXTEND and MONARCH) presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of post hoc analysis examining outcomes for patients who switched from tocilizumab in ASCERTAIN to open-label sarilumab in EXTEND presented at the 19th Annual Congress of the European League Against Rheumatism
    • 09 May 2018 Results (n=901) assessing long-term safety, efficacy and tolerability of sarilumab, added to disease-modifying antirheumatic drugs (DMARDs), in patients with active rheumatoid arthritis (RA), were published in the Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top